Key Points AbbVie survived Humira’s patent cliff. Its new billion-dollar drugs are picking up the slack. 10 stocks we like better than AbbVie › AbbVie (NYSE: ABBV) , one of the world's largest pharmaceutical companies , has been a reliable long-term investment. It's raised its dividend annually for 53 consecutive years, making it a Dividend King that has increased its payout for at least 50 years in a row, and a dozen of its drugs generate more than $1 billion in annual revenue. But as the 10-year Treasury yield stays above 5% -- its highest level since 2007 -- is it still smart to buy and hold this dividend stock? Image source: Getty Images. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.